ADMA Biologics
Manufacturing · New Jersey, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
465 State Rt 17, Ramsey, New Jersey, 074...Phone Number
(201) 478-5552Website
www.admabiologics.comRevenue
$512.3 MillionStock Symbol
ADMAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About ADMA Biologics
Founded in 2004, ADMA Biologics is a commercial biopharmaceutical company that focuses on manufacturing, marketing, and developing products for immunodeficient patients at risk for infection. The company is headquartered in Ramsey, New Jersey.Explore more
ADMA Biologics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ADMA Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if ADMA Biologics is spiking on competitors!
Product Launch: Get notified when ADMA Biologics launches new products
Click to see if ADMA Biologics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ADMA Biologics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on ADMA Biologics recently announced quarterly report
Funding: Get notified immidiatlly once ADMA Biologics has new funding data
Check if ADMA Biologics has recently received funding, and reach out quickly before it becomes old news!
ADMA Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at ADMA Biologics
Find 3 more new buyers
Compare Similar Companies to ADMA Biologics
Compare insights from companies similar to ADMA Biologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ADMA Biologics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ADMA Biologics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ADMA Biologics.
ADMA Biologics financials insights
Gather financial insights about ADMA Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$15M
Corporate Investment
$5M
2015
Stock Offering
$10.3M
Debt
$21M
2016
Stock Offering
$14.1M
Debt
$4M
2017
Debt
$30M
Stock Offering
$39.1M
2018
Stock Offering
$40M
2019
Stock Offering
$51.8M
2020
Stock Offering
$82.3M
Debt
$100M
ADMA Biologics Tech Stack
A closer look at the technologies used by ADMA Biologics
Most Recent Scoops
Earnings
ADMA Biologics has reported gross profit of $86.3 million for Q2 2026, resulting in a gross margin of 69%, compared to 55% in the prior year period, with margin expansion primarily driven by continued incentive mix expansion and the ongoing benefits of the company's yield-enhanced manufacturing process.
Earnings, Finance, Manufacturing Operations
Project
ADMA Biologics has completed a real-world outcomes analysis comparing patient health metrics during the 12 months before and after initiation of incentive treatment, finding statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, oral antibiotic use, corticosteroid use, and infection-related emergency room visits.
Medical Research
Earnings
ADMA Biologics has reported adjusted EBITDA of $61.8 million for Q2 2026, increasing 22% year-over-year, adjusted net income of $39 million, increasing 8% year-over-year, and GAAP net income of $37.8 million, increasing 11% year-over-year.
Earnings, Finance
Earnings
reported cash from operations of approximately $30 million for Q2 2026, with accounts receivable of $138.2 million at quarter-end and days sales outstanding of approximately 101 days, improving from approximately 107 days at the end of Q1 2026, with the company targeting days sales outstanding between 90 to 105 days for the second half of 2026.
Earnings, Accounting, Billing & Invoice, Financial Reporting, Finance, Financial Operations
Earnings
Earnings, Accounting, Financial Planning, Financial Reporting, Finance, Financial Strategy
ADMA Biologics News & Media
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder...ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the...Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
PHILADELPHIA, Aug. 17, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on...ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ADMA Biologics
Sign Up For FreeTo access detailed company insights
Founded in 2004, ADMA Biologics is a commercial biopharmaceutical company that focuses on manufacturing, marketing, and developing products for immunodeficient patients at risk for infection. The company is headquartered in Ramsey, New Jersey.... Read More
